[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

Na et al., 2008 - Google Patents

Capillary electrophoretic separation of high-molecular-weight poly (ethylene glycol)-modified proteins

Na et al., 2008

Document ID
3866845201133513489
Author
Na D
Park E
Jo Y
Lee K
Publication year
Publication venue
Analytical biochemistry

External Links

Snippet

This study was designed to demonstrate the utility of capillary electrophoresis (CE) for separating high-molecular-weight poly (ethylene glycol)(PEG)-conjugated proteins. As a CE method, sodium dodecyl sulfate–capillary gel electrophoresis (SDS–CGE) was applied to …
Continue reading at www.sciencedirect.com (other versions)

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives
    • A61K47/48—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates
    • A61K47/48169—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates the modifying agent being an organic macromolecular compound, i.e. an oligomeric, polymeric, dendrimeric molecule
    • A61K47/48192—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates the modifying agent being an organic macromolecular compound, i.e. an oligomeric, polymeric, dendrimeric molecule the organic macromolecular compound has been obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas, polyurethanes
    • A61K47/48215—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates the modifying agent being an organic macromolecular compound, i.e. an oligomeric, polymeric, dendrimeric molecule the organic macromolecular compound has been obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas, polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer, dendrimer, e.g. PEG, PPG, PEO, polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/215—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives
    • A61K47/06—Organic compounds, e.g. mineral oil, petrolatum, synthetic polyolefins
    • A61K47/16—Organic compounds, e.g. mineral oil, petrolatum, synthetic polyolefins containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Quaternary ammonium compounds, e.g. amides, ureas
    • A61K47/183—Amino acids or aminosulphonic acids, e.g. glycine, EDTA, aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives
    • A61K47/48—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates
    • A61K47/48007—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates the pharmacologically- or therapeutically-active agent being covalently bound or complexed to a modifying agent

Similar Documents

Publication Publication Date Title
Foser et al. Isolation, structural characterization, and antiviral activity of positional isomers of monopegylated interferon α-2a (PEGASYS)
US20240174726A1 (en) Hepcidin analogues and uses thereof
Ramon et al. PEGylated interferon-α2b: a branched 40K polyethylene glycol derivative
Youn et al. Improved intrapulmonary delivery of site-specific PEGylated salmon calcitonin: optimization by PEG size selection
Na et al. Stability of PEGylated salmon calcitonin in nasal mucosa
Wylie et al. Carboxyalkylated histidine is a pH-dependent product of pegylation with SC-PEG
da Silva Freitas et al. Biochemical and biophysical characterization of lysozyme modified by PEGylation
CN102617736B (en) The stable interferon alpha polyoxyethylene glycol conjugate represented by a kind of positional isomers
Scaramuzza et al. A new site-specific monoPEGylated filgrastim derivative prepared by enzymatic conjugation: production and physicochemical characterization
Na et al. Capillary electrophoretic separation of high-molecular-weight poly (ethylene glycol)-modified proteins
Na et al. Identification of the modifying sites of mono-PEGylated salmon calcitonins by capillary electrophoresis and MALDI–TOF mass spectrometry
Na et al. Capillary electrophoretic characterization of PEGylated human parathyroid hormone with matrix-assisted laser desorption/ionization time-of-flight mass spectrometry
Park et al. Characterization of the reversed-phase chromatographic behavior of PEGylated peptides based on the poly (ethylene glycol) dispersity
Gerislioglu et al. Characterization of singly and multiply PEGylated insulin isomers by reversed-phase ultra-performance liquid chromatography interfaced with ion mobility mass spectrometry
Qian et al. Development of a high performance size exclusion chromatography method to determine the stability of Human Serum Albumin in a lyophilized formulation of Interferon alfa-2b
Jo et al. Long-acting interferon-α 2a modified with a trimer-structured polyethylene glycol: Preparation, in vitro bioactivity, in vivo stability and pharmacokinetics
Na et al. Sodium dodecyl sulfate‐capillary gel electrophoresis of polyethylene glycolylated interferon alpha
Cai et al. Separation of exenatide analogue mono-PEGylated with 40 kDA polyethylene glycol by cation exchange chromatography
Tong et al. Characterization of a monoPEG20000-Endostar
Goolcharran et al. Comparison of the rates of deamidation, diketopiperazine formation, and oxidation in recombinant human vascular endothelial growth factor and model peptides
Youn et al. Chromatographic separation and mass spectrometric identification of positional isomers of polyethylene glycol-modified growth hormone-releasing factor (1-29)
Lu et al. Elucidation of PEGylation site with a combined approach of in-source fragmentation and CID MS/MS
Son et al. Structural identification and biological activity of positional isomers of long-acting and mono-PEGylated recombinant human granulocyte colony-stimulating factor with trimeric-structured methoxy polyethylene glycol N-hydroxysuccinimidyl functional group
Kemptner et al. GEMMA and MALDI-TOF MS of reactive PEGs for pharmaceutical applications
Peng et al. N-terminal site-specific PEGylation enhances the circulation half-life of Thymosin alpha 1